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INTRODUCTION
Some authors have stated that the therapeutic 
use of autologous platelet-rich plasma (PRP) 
could be a potential advance in the stimulation 
and acceleration of soft-tissue healing and bone 
regeneration1,2. Platelets have a rich store of 
factors and cytokines within their alpha granu-
les and dense granules, which makes PRP an 
appealing therapeutic alternative. Some of the 
important factors found within the alpha granu-
les of the platelet include platelet-derived growth 
factor (PDGF), transforming growth factor-beta 
(TGF-), insulin-like growth factor-1 (IGF-1), 
vascular endothelial growth factor (VEGF), and 
epidermal growth factor (EGF), among others1. 
The dense granules of the platelet contain neuro-
modulators and inflammatory modulators such 
as histamine and serotonine. Platelets are stimu-
lated to release these growth factors and cytoki-
nes by exposure either to collagen or to thrombin 
and calcium. The purpose of this review article is 
to summarize the existing knowledge on the role 
of PRP in the treatment of sports injuries of the 
knee based on the studies published in PubMed 
until 1 July 2011, and to make a rigorous review 
of the methodology and results of the various 
animal and clinical studies published so far on 
the topic.
THE ROLE OF PLATELET-RICH PLASMA (PRP) IN THE TREATMENT OF SPORTS 
INJURIES OF THE KNEE 
EL PAPEL DEL PLASMA RICO EN PLAQUETAS (PRP) EN LAS LESIONES DEPORTIVAS 
DE LA RODILLA
ACL INJURIES
A collagen-PRP scaffold was used by Murray 
et al to treat a central ACL defect in vivo in 
a canine model3. Their hypothesis was that a 
beneficial biologic repair response can be indu-
ced by placing a collagen-platelet rich plasma 
(collagen-PRP) material into a central ACL 
defect. They used a collagen-PRP scaffold to 
treat a central ACL defect in vivo. In a first ex-
periment, the histologic response in treated and 
untreated defects was evaluated at 3 and 6 weeks. 
In a second experiment, biomechanical testing of 
the treated ligaments was performed at 6 weeks 
and compared with the results of biomechanical 
testing of untreated defects at the same time-
point. The percentage filling of the defects in the 
treated ACLs was significantly higher at both 
the 3- and 6-week time-points when compared 
with the untreated contralateral control defects. 
Biomechanically, the treated ACL defects had a 
40% increase in strength at 6 weeks, which was 
significantly higher than the 14% increase in 
strength previously reported for untreated de-
fects. The main conclusion was that placement 
of a collagen-PRP bridging scaffold in a central 
ACL defect can stimulate healing of the ACL 
histologically and biomechanically. The ACL 
fails to heal after suture repair. One hypothesis 
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for this failure is the premature loss of the fibrin 
clot, or provisional scaffolding, between the two 
ligament ends in the joint environment. To test 
this hypothesis, in a porcine model a substitute 
provisional scaffold of collagen-PRP hydrogel 
was used by Murray et al to fill the ACL wound 
site at the time of suture repair and the structural 
properties of the healing ACLs evaluated 4 weeks 
after surgery4. The supplementation of suture 
repair with a collagen-PRP hydrogel resulted in 
significant improvements in load at yield, maxi-
mum load, and linear stiffness at 4 weeks. Their 
main conclusion was that use of a stabilized pro-
visional scaffold, such as a collagen-PRP hydro-
gel, to supplement primary repair of the ACL can 
result in improved biomechanical properties at 
an early time point. However, Murray et al stated 
that further studies were needed to determine the 
long-term effect of primary repair enhancement4.
Murray et al, reported that use of a collagen-
PRP scaffold in a canine model can ameliorate 
histologic differences noted between healing 
extra-articular ligamentous wounds and non-
healing intra-articular ligamentous wounds5. 
Their study supported the hypothesis that pre-
mature scaffold failure may play a key role in 
the normally expected failure of the ACL to heal 
after injury. However, in a porcine model the use 
of PRP alone to supplement suture repair of the 
ACL was ineffective6.
Silva and Sampaio performed a prospective stu-
dy in four groups of patients undergoing ACL 
reconstruction with hamstring tendons: without 
PRP; with PRP in femoral tunnels at the end of 
surgery; with PRP in femoral tunnels at the end 
of surgery and intra-articular at 2- and 4 weeks 
after surgery; with PRP activated with thrombin 
in the femoral tunnels7. All patients underwent 
magnetic resonance imaging (MRI) of the knee 3 
months after surgery to evaluate the signal inten-
sity of the fibrous interzone (FIZ) in the femoral 
tunnels. The authors did not find any difference 
among the groups when comparing the signal 
intensity of the FIZ on MRI.
Nin et al, compared the clinical and inflamma-
tory parameters with the addition of platelet-
derived growth factor (PDGF) in primary ACL 
reconstruction with bone-patellar tendon-bone 
(BPTB) allograft in a clinical prospective, rando-
mized, double-blind study8. The use of PDGF, on 
the graft and inside the tibial tunnel, in patients 
treated with bone-patellar tendon-bone allogra-
fts had no discernable clinical or biomechanical 
effect at 2 years’ follow-up. Nin et al also stated 
that more clinical studies were needed to show 
the efficacy and use of these factors in daily prac-
tice in ACL reconstruction8.
Sanchez et al, presented a review on the present 
and future use of PRP in the reconstruction of 
the ACL9. Although their findings were not con-
clusive, the use of autologous PRP seemed to be 
safe, reproducible, and effective in mimicking the 
natural processes of soft tissue and bone healing. 
In another study the same authors investigated 
whether the application of a particular PRP pre-
paration rich in growth factors (PRGF) during 
ACL surgery gives a potential advantage for 
better tendon graft ligamentization10. The clinical 
study was observational and retrospective (low 
grade of evidence), using hyaluronan injections 
as a control. Sanchez et al concluded that the use 
of PRGF influenced the histologic characteristics 
of tendon grafts, resulting in more remodeling 
compared with untreated grafts10. However, 
they also stated that although these preliminary 
results need to be evaluated in a randomized cli-
nical trial, they provide useful information about 
the safety of PRGF and open new perspectives on 
autologous treatments for joint diseases.
Vogrin et al, tried to improve knee stability after 
ACL reconstruction with a hamstring graft and 
use of platelet-derived growth factors11. Plate-
let-leukocyte gel was produced from platelet-
leukocyte-rich plasma prepared from a unit of 
whole blood in an autologous platelet separator. 
The gel was applied locally, after hamstring gra-
ft placement. Fifty patients were included in a 
prospective study: 25 in the platelet gel group, 25 
in a control group. They evaluated anteroposte-
rior knee stability with the KT-2000 arthrometer 
before surgery and at 3 and 6 months after sur-
gery. Patients treated with the gel demonstrated 
significantly better anteroposterior knee stability 
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than patients in the control group. The calcula-
ted improvements in knee stability at 6 months 
were 1.3 +/- 1.8 mm in the control group and 3.1 
+/- 2.5 mm in the platelet gel group (statistically 
significant difference). Vogrin et al concluded 
that platelet-leukocyte gel, applied locally, could 
improve knee stability in surgery for reconstruc-
tion of the ACL11. However, as the number of 
patients of this study is very low, the conclusions 
must be considered as preliminary.
Magarian et al, searched for age dependence in 
human fibroblasts12. Human fibroblasts were 
obtained from 10 immature and adolescent pa-
tients, based on a-priori power calculations, and 
cultured in a collagen-PRP composite. Three 
parameters that are pivotal for defect remodeling 
and wound healing-cell migration, cell prolife-
ration, and scaffold contraction-were chosen 
as endpoints. Both migration and proliferation 
were significantly higher in immature cells, but 
no differences were seen in wound contraction. 
The findings of this preliminary study suggested 
that immature patients respond more favorably 
to treatment with PRP.
Vogrin et al, tried to determine if the use of platelet 
gel (PG) accelerates early graft revascularization 
after ACL reconstruction in the clinical setting13. 
PG was produced from autologous PRP and 
applied locally. PG was produced from autolo-
gous platelet-rich plasma and applied locally. 
They quantitatively evaluated the revasculariza-
tion process in the osteoligamentous interface 
zone in the bone tunnels and in the intra-articular 
part of the graft by means of contrast-enhanced 
magnetic resonance imaging (MRI). After 4-6 
weeks, the PG-treated group demonstrated a 
significantly higher level of vascularization in 
the osteoligamentous interface than the control 
group. In the intra-articular part of the graft, they 
found no evidence of revascularization in either 
group. Vogrin et al, concluded that locally applied 
PG seems to enhance early revascularization of 
the graft in the osteoligamentous interface zone 
after ACL reconstruction.
Vavken and Murray assessed the feasibility of 
successfully repairing the torn ACL in several 
large animal models of primary repair of partial 
and complete ACL transection over 4 to 14 wee-
ks14. A bioactive and biocompatible scaffold was 
developed. This biomaterial showed promising 
functional, suggesting potential for a successful, 
future clinical application.
Vavken et al, study tested whether the strength of 
a tissue-engineered ACL repair is associated with 
VEGF receptors’ mRNA expression of ACL cells 
and whether age influences this association in a 
porcine model15. Nineteen female Yucatan pigs 
underwent enhanced ACL repair. Biomechanical 
testing was performed after 15 weeks of healing. 
Messenger RNA of VEGF receptors 1 and 2 in 
ACL fibroblasts was assessed by RT-PCR. The 
ACL structural properties were regressed on re-
ceptor expression levels in a multivariate model 
including serum levels of VEGF, age, and weight 
as potential confounders. While maximum load 
and linear stiffness were independent of VEGF 
receptor expression, VEGF receptor 1 was asso-
ciated with displacement (positively) and yield 
load (negatively). In a multivariate model of 
VEGF receptor expression and biomechanics, 
age was associated with maximum load and yield 
load. Vavken et al, suggested that high VEGF 
receptor expression, even more so at higher age, 
results in a more compliant scar, which in turn 
may lead to greater knee laxity and a compromi-
sed clinical result15.
According to Mastrangelo, et al16, enhanced 
primary repair of the ACL using a collagen 
scaffold loaded with platelets seems to improve 
the functional healing of suture repair in animal 
models. In their study, Mastrangelo et al, tried to 
determine if lowering the platelet concentration 
would reduce the structural properties of the 
repaired ACL and increase postoperative knee 
laxity16. Eight Yucatan mini-pigs underwent bi-
lateral suture repair. In one knee, the repair was 
augmented with a collagen scaffold saturated 
with platelet-rich plasma (PRP) containing five 
times the systemic baseline of platelets (5×) whi-
le the contralateral knee had a collagen scaffold 
saturated with PRP containing three times the 
systemic baseline of platelets (3×). After 13 
weeks of healing, knee joint laxity and the struc-
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rabbit menisci and left empty or filled with hyalu-
ronan-collagen composite matrices without cells, 
loaded with platelet-rich plasma, autologous 
bone marrow, or autologous mesenchymal stem 
cells. The study showed the necessity of MSCs 
for the repair of meniscal defects in the avascular 
zone. MSCs seemed to fulfill additional repair 
qualities besides the delivery of growth factors. 
In a review article Shybut and Strauss stated that 
for complex, recurrent, or avascular zone tears, 
particularly when surgery is limited to meniscal 
work, consideration can be given to augmenting 
the repair with a fibrin clot or PRP20. However, it 
was just an opinion of the authors, not based in 
scientific evidence.
JUMPER´S KNEE (PATELLAR 
TENDINOPATHY)
Kon et al, described a minimally invasive way 
to apply PRP growth factors to chronic patellar 
tendinopathy in male athletes21. Twenty male 
athletes with a mean history of 20.7 months of 
pain received treatment, and outcomes were 
prospectively evaluated at 6 months follow-up. 
No severe adverse events were observed, and sta-
tistically significant improvements in all scores 
were recorded. The results of this preliminary 
study suggested that the method could be safely 
used for the treatment of jumper’s knee, by aiding 
the regeneration of tissue which otherwise has 
low healing potential. Filardo et al evaluated the 
efficacy of multiple PRP injections on the healing 
of chronic refractory patellar tendinopathy after 
previous classical treatments have failed22. They 
treated 15 patients affected by chronic jumper’s 
knee, who had failed previous nonsurgical or 
surgical treatments, with multiple PRP injections 
and physiotherapy. They also compared the 
clinical outcome with a homogeneous group of 
16 patients primarily treated exclusively with the 
physiotherapy approach. The clinical results of 
this retrospective study were encouraging, indi-
cating that PRP injections could have the poten-
tial to promote the achievement of a satisfactory 
clinical outcome, even in difficult cases with 
chronic refractory tendinopathy after previous 
classical treatments have failed.
tural properties of the ACL were measured. The 
3× platelet concentration resulted in a 24.1% 
decrease in cellular density of the repair tissue, 
but did not significantly decrease the structural 
properties for the yield load and linear stiffness, 
respectively]. The 3× platelet concentration also 
did not significantly change the mean antero-
posterior knee laxity at 30° and 90° of flexion but 
did result in a lower AP laxity at 60°. The main 
conclusion of that animal experiment was that 
the decrease in platelet concentration from 5× 
to 3× to enhance suture repair of the ACL did 
not significantly harm the mechanical outcomes.
In a prospective randomized controlled clinical 
study, Cervellin et al, evaluated whether PRP 
was able to reduce the anterior knee pain, the 
kneeling pain, and donor-site morbidity17. In 
other words, they evaluated whether platelet-rich 
plasma (PRP), due to its anti-inflammatory pro-
perties and capacity to stimulate tissue regenera-
tion, was able to reduce the anterior knee pain, 
the kneeling pain, and donor-site morbidity. 
Forty young athletes with the indication of ACL 
reconstruction with patellar tendon grafts were 
randomly assigned to group A (n = 20 patients, 
control group) or group B (n = 20 patients, PRP 
group). The autologous PRP gel was applied to 
both the patellar and tendon bone plug harvest 
site and stabilized by the peritenon suture. The 
study showed the usefulness of PRP in reducing 
subjective pain at the donor-site level after ACL 
reconstruction with BPTB. However, Cervelli 
et al stated that this approach deserves further 
investigations to confirm PRP efficacy and to 
elucidate its mechanism of action.
MENISCAL DEFECTS
Ishida et al, tested the hypothesis that PRP 
enhances meniscal tissue regeneration in vitro 
(monolayer meniscal cell cultures) and in vivo 
(rabbit meniscus)18. The findings of their study 
suggested that PRP seems to enhance the hea-
ling of meniscal defects. Zellner et al, examined 
the role of MSCs in meniscal tissue repair in a 
rabbit model19. Circular meniscal punch defects 
(2 mm) were created in the avascular zone of 
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RESUMEN
El plasma rico en plaquetas (PRP) se está uti-
lizando cada vez más. Usando como palabras 
clave “PRP” y “knee” (rodilla) se hizo una bús-
queda en PubMed sobre el uso del PRP en las 
lesiones deportivas de la rodilla. Se encontraron 
22 artículos. Muchos de ellos fueron estudios 
realizados en animales y el resto estudios sin 
grupo control llevados a cabo en humanos y pu-
blicados en revistas de rigor científico modesto. 
Dichos estudios animales y humanos sugieren 
que la colocación de un andamio en puente de 
colágeno-PRP en el defecto central del LCA 
podría estimular biomecánicamente e histológi-
camente su cicatrización. También que las inyec-
ciones intra-articulares de PRP podrían mejorar 
la cicatrización de defectos meniscales. Por últi-
mo, que las inyecciones de PRP podrían promo-
ver resultados satisfactorios en casos de rodilla 
de saltador (tendinitis rotuliana). Teniendo en 
cuenta la baja calidad de los datos publicados 
en la bibliografía y tras realizar una valoración 
objetiva del valor del PRP en las indicaciones 
previamente mencionadas, mi conclusión es que 
el PRP es todavía es un tratamiento experimen-
tal, que en muchos casos no ha demostrado tener 
un valor significativo en cuanto a sus efectos.
Palabras clave: PRP (plasma rico en plaquetas).
Lesiones deportivas. Rodilla.
SUMMARY
The use of platelet-rich plasma (PRP) is beco-
ming increasingly available. PubMed articles 
related to the use of PRP in sports injuries of 
the knee were searched using the following key 
words: PRP and knee. A total of 22 reports 
were found. Many of them were animal studies 
and the rest were human clinical studies with 
no controls and published in journals that do 
not expect as much rigour in the scientific va-
lidity. The aforementioned animal experiments 
and clinical studies suggest that placement of 
a collagen-PRP bridging scaffold in a central 
ACL defect can stimulate healing of the ACL 
histologically and biomechanically. Also that in-
tra-articular injections of PRP can enhance the 
healing of meniscal defects. Finally, that PRP 
injections can have the potential to promote the 
achievement of a satisfactory clinical outcome 
in cases of jumper´s knee (patellar tendinopa-
thy). Taking into account the low quality of the 
data reported in the literature and after perfor-
ming an objective view of the value of PRP for 
the various indications, my conclusion is that 
PRP is a treatment that is still experimental and 
in many instances shown to be not significant 
in its effects.
Key words: Platelet-rich plasma (PRP). Sports 
injuries. Knee.
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